We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+57.48%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$514M
AUM Growth
-$7.79M
Cap. Flow
+$53.2M
Cap. Flow %
10.35%
Top 10 Hldgs %
56.23%
Holding
206
New
96
Increased
32
Reduced
19
Closed
50

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.5M
2
AZN icon
AstraZeneca
AZN
+$18.2M
3
MRNA icon
Moderna
MRNA
+$12.1M
4
XWEL icon
XWELL
XWEL
+$6.41M
5
CVM icon
CEL-SCI Corp
CVM
+$3.62M

Sector Composition

Rank Sector Weight
1 Miscellaneous 75.72%
2 Healthcare 15.57%
3 Consumer Staples 2.16%
4 Technology 1.81%
5 Financials 1.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MGNX icon
101
PUT
MacroGenics
MGNX
$258M
$580K 0.11%
+182
New +$4.42K
HEPA
102
DELISTED
Hepion Pharmaceuticals
HEPA
$564K 0.11%
+306
New +$671K
CTXR icon
103
Citius Pharmaceuticals
CTXR
$15.4M
$559K 0.11%
+12,560
New +$500K
BFLY icon
104
Butterfly Network
BFLY
$2.07B
$556K 0.11%
+33,047
New +$654K
BKYI
105
PUT
BIO-key International
BKYI
$3.68M
$547K 0.11%
+9
New +$6.5K
BIOC
106
PUT
DELISTED
Biocept, Inc.
BIOC
$528K 0.1%
35
+19
+119% +$3.45K
IWM icon
107
iShares Russell 2000 ETF
IWM
$76.8B
$524K 0.1%
+2,372
New +$518K
NCTY
108
CALL
The9 Ltd
NCTY
$60.6M
$524K 0.1%
+17
New +$5.8K
BCLI
109
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$523K 0.1%
+9,107
New +$688K
ATOS icon
110
Atossa Therapeutics
ATOS
$24.7M
$511K 0.1%
+16,149
New +$590K
BPTH
111
DELISTED
Bio-Path Holdings Inc
BPTH
$505K 0.1%
+3,596
New +$426K
STKH
112
Steakholder Foods
STKH
$2.24M
$501K 0.1%
+45
New +$546K
NCTY
113
PUT
The9 Ltd
NCTY
$60.6M
$487K 0.09%
+16
New +$5.46K
MITO
114
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$473K 0.09%
+301,575
New +$518K
AVEO
115
PUT
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$454K 0.09%
620
-6,851
-92% -$59.1K
PHIO icon
116
PUT
Phio Pharmaceuticals
PHIO
$11.5M
$427K 0.08%
+15
New +$4.99K
ADTX
117
DELISTED
ADITXT INC
ADTX
0
DCOY
118
Decoy Therapeutics
DCOY
$1.72M
$395K 0.08%
+7
New +$401K
UK icon
119
Ucommune International Ltd Class A Ordinary Shares
UK
$1.36M
$386K 0.08%
+54
New +$512K
NMRD
120
PUT
DELISTED
Nemaura Medical, Inc. Common Stock
NMRD
$383K 0.07%
+501
New +$3.32K
TTNP
121
PUT
DELISTED
Titan Pharmaceuticals
TTNP
$376K 0.07%
+63
New +$4.17K
BIOC
122
DELISTED
Biocept, Inc.
BIOC
$313K 0.06%
2,049
+996
+95% +$181K
DMK
123
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$285K 0.06%
43
+21
+95% +$1.64K
NBRV
124
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$272K 0.05%
6,560
-3,840
-37% -$239K
RYM
125
RYTHM Inc
RYM
$46.7M
$266K 0.05%
+7
New +$290K

Similar funds

Sabby Management's Q1 2021 Portfolio in Review

As of Q1 2021, Sabby Management held 206 positions worth $514M, down 1.5% from $522M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sabby Management deployed $53.2M of net new capital in Q1 2021, opening 96 new positions and adding to 32 existing holdings. Its largest new stake was Sorrento Therapeutics, Inc.: 1,064,933 shares worth $8.81M.

By sector, the portfolio is most concentrated in Miscellaneous at 76% of assets, down from 81% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was AVEO Pharmaceuticals, Inc., an estimated $494K trimmed.

  • Sabby Management's largest Q1 2021 buy was Sorrento Therapeutics, Inc.: 1,064,933 shares worth $8.81M.
  • Sabby Management added most to Odonate Therapeutics, Inc. Common Stock in Q1 2021, an estimated $11.1M increase.
  • Sabby Management's biggest Q1 2021 reduction was AVEO Pharmaceuticals, Inc., cutting an estimated $494K.
  • Sabby Management fully exited Biogen in Q1 2021, selling an estimated $31.5M.
  • Sabby Management's ten largest holdings make up 56% of its $514M portfolio in Q1 2021.
  • Sabby Management opened 96 new positions and closed 50 in Q1 2021.
  • Sabby Management's portfolio value fell 1.5% quarter-over-quarter to $514M.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.